Colgate-Palmolive Company CL enters the second half of 2026 with better operating momentum. Volumes are improving, margins have held up better than expected and management lifted its Base Business earnings outlook.
The restraint is valuation. CL still trades above its sub-industry, sector and the broader market, while weakness in North America leaves less room for execution misses.
Colgate’s Growth Mix Is Getting Healthier
Second-quarter organic sales rose 2.4%, with organic volume up 0.8% and pricing contributing 1.6%. Worldwide organic volume improved sequentially for a third straight quarter, giving Colgate a more balanced growth mix than one driven mainly by price.
Colgate-Palmolive Company Price, Consensus and EPS Surprise
Colgate-Palmolive Company price-consensus-eps-surprise-chart | Colgate-Palmolive Company Quote
Emerging markets added breadth, with organic sales up 4.8%. Latin America rose 5.3% and Asia Pacific increased 5.2%, while management expects the second half to be somewhat more volume-driven as innovation and brand penetration efforts scale.
CL’s Margin Outlook Improves Despite Higher Costs
Gross profit margin expanded 140 basis points year over year to 61.5% in the second quarter. Revenue growth management, productivity, pricing and mix helped absorb higher investment, including a 15% increase in advertising.
Management now expects full-year gross profit margin to be roughly flat year over year, versus a prior expectation for a decline. That upgrade matters because raw-material and tariff costs are still expected to be higher in the second half than in the second quarter.
Colgate’s North America Weakness Caps the Upside
North America remains the clearest operating drag. Second-quarter organic sales fell 3% and organic volume declined 3.9% as softer U.S. categories, retailer inventory reductions, heavier competition and some market-share loss pressured results.
Competitive intensity is meaningful. The Procter & Gamble Company PG competes in oral care through brands including Crest and Oral-B, while The Clorox Company CLX has a broad home-care portfolio. Colgate plans selective pricing and promotional actions, but persistent category softness could slow the volume recovery.
CL’s Valuation Leaves Less Room for Error
CL trades at 22.47X forward 12-month earnings, above the Zacks sub-industry’s 18.38X, the sector’s 17.2X and the S&P 500’s 20.6X. That premium raises the hurdle for further upside if U.S. demand or cost pressures worsen.
Image Source: Zacks Investment Research
The stock is not at an extreme relative to its own history. Its current multiple sits below the five-year median of 23.5X, with the five-year range spanning 19.4X to 28.8X. The valuation therefore looks elevated versus external benchmarks but less stretched versus Colgate’s historical norm.
Colgate’s Earnings Revisions Add Support
The Zacks Consensus Estimate for earnings in the current fiscal year has moved higher, with the estimate up 1.3% over four weeks and 1.1% over 12 weeks. Second-quarter Base Business earnings of 99 cents per share also beat the consensus mark of 95 cents by 4.2%.
Projected EPS growth for the current fiscal year is 4.3%. That keeps the valuation-growth trade-off in focus because estimate revisions are favorable, but the expected earnings growth rate remains modest relative to the stock’s forward multiple.
CL’s Mixed Style Scores Reinforce Patience
The operating picture has improved, but the valuation premium and North American pressure argue for patience rather than treating recent progress as an unqualified buying signal. CL currently carries a Zacks Rank #3 (Hold), consistent with a balanced near-term stance. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CL has a VGM Score of B, a Growth Score of B and a Momentum Score of B, but a Value Score of D. The B grades are favorable within their respective styles, while the Value Score is a counterweight. Because the Zacks Style Scores complement the Zacks Rank, the mix shows favorable growth and momentum characteristics alongside weaker value characteristics.
Research Chief Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Colgate-Palmolive Company (CL) : Free Stock Analysis Report
Procter & Gamble Company (The) (PG) : Free Stock Analysis Report
The Clorox Company (CLX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
